ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
- Conditions
- Small Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT03406156
- Locations
- 🇺🇸
Oncology Hematology Care, Inc. /ID# 202397, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology-Nashville Centennial /ID# 201098, Nashville, Tennessee, United States
🇺🇸Arizona Oncology Associates, PC-HOPE /ID# 202335, Tempe, Arizona, United States
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
- Conditions
- Cancer - Ovarian
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03400306
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1242
- Registration Number
- NCT03398135
- Locations
- 🇨🇳
Wuxi People's Hospital /ID# 218797, Wuxi, Jiangsu, China
🇨🇳Shengjing Hospital of China Medical University /ID# 211643, Shenyang, Liaoning, China
🇨🇳Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 211230, Shanghai, Shanghai, China
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1558
- Registration Number
- NCT03398148
- Locations
- 🇺🇸
Louisana Research Center, LLC /ID# 201204, Shreveport, Louisiana, United States
🇺🇸Massachusetts General Hospital - Crohn's and Colitis Center /ID# 164255, Boston, Massachusetts, United States
🇺🇸University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 158524, Ann Arbor, Michigan, United States
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- Drug: Placebo solution for IV infusion on Day 15
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 142
- Registration Number
- NCT03391765
- Locations
- 🇺🇸
Usc /Id# 165529, Los Angeles, California, United States
🇺🇸University of California, Los Angeles /ID# 165669, Los Angeles, California, United States
🇮🇹IRCCS San Camillo /ID# 201229, Venice, Italy
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
- Conditions
- Blastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 179
- Registration Number
- NCT03386513
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, United States
A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)
- Conditions
- Polyarticular Juvenile Arthritis
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT03383263
- Locations
- 🇷🇺
Chelyabinsk Regional Children's Clinical Hospital /ID# 204829, Chelyabinsk, Chelyabinskaya Oblast, Russian Federation
🇷🇺Republican Children's Clinical Hospital /ID# 204830, Ufa, Bashkortostan, Respublika, Russian Federation
🇷🇺Saratov State Medical University n.a. V.I. Razumovskiy /ID# 206319, Saratov, Saratovskaya Oblast, Russian Federation
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT03374917
- Locations
- 🇺🇸
Univ Kansas Med Ctr /ID# 166280, Kansas City, Kansas, United States
🇺🇸Loma Linda University /ID# 165592, Loma Linda, California, United States
🇺🇸Compass Research /ID# 167329, Orlando, Florida, United States
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT03368859
- Locations
- 🇺🇸
USC Norris Cancer Center /ID# 200410, Los Angeles, California, United States
🇺🇸University of California, Los /ID# 169294, Santa Monica, California, United States
🇺🇸Florida Cancer Specialist - South /ID# 203796, Fort Myers, Florida, United States
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
- Conditions
- Parkinson's Disease (PD)
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 412
- Registration Number
- NCT03362879
- Locations
- 🇷🇴
Colentina Clinical Hospital /ID# 169263, Bucharest, Romania
🇷🇴Emergency Clinical County Hosp /ID# 169269, Targu Mures, Romania
🇨🇦Ottawa Hospital /ID# 169448, Ottawa, Ontario, Canada